Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S, Xiong A, Yu J, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C.
Ren S, et al. Among authors: liu y, liu c, liu t.
Cancer Immunol Immunother. 2024 May 10;73(7):124. doi: 10.1007/s00262-024-03715-4.
Cancer Immunol Immunother. 2024.
PMID: 38727837
Free PMC article.
Clinical Trial.